ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för vortioxetine. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

25 träffar

Bibliografisk träff 2013-10-01

Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.

Chen G, Lee R, Højer AM, Buchbjerg JK, Serenko M, Zhao Z.

Clin Drug Investig · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1007/s40261-013-0117-6

Bibliografisk träff 2013-09-07

Serotonergic receptor mechanisms underlying antidepressant-like action in the progesterone withdrawal model of hormonally induced depression in rats.

Li Y, Raaby KF, Sánchez C, Gulinello M.

Behav Brain Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.bbr.2013.09.002

Bibliografisk träff 2013-08-02

Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism.

du Jardin KG, Jensen JB, Sanchez C, Pehrson AL.

Eur Neuropsychopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.euroneuro.2013.07.001

Bibliografisk träff 2013-08-01

Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction.

Pehrson AL, Sanchez C.

CNS Spectr · review-article; review; journal article · DOI 10.1017/s1092852913000540

Bibliografisk träff 2013-05-28

Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice.

Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, Gardier AM, Hen R, Ebert B, Miller S, Sanchez C, David DJ.

Neuropharmacology · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neuropharm.2013.05.014

Bibliografisk träff 2013-05-01

Serotonergic drugs for depression and beyond.

Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA.

Curr Drug Targets · review; journal article · DOI 10.2174/1389450111314050007

Bibliografisk träff 2013-02-20

A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition.

Theunissen EL, Street D, Højer AM, Vermeeren A, van Oers A, Ramaekers JG.

Clin Pharmacol Ther · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1038/clpt.2013.39

Bibliografisk träff 2013-02-18

5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects.

Stenkrona P, Halldin C, Lundberg J.

Eur Neuropsychopharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.euroneuro.2013.01.002

Bibliografisk träff 2013-02-01

Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats.

Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C.

Pharmacol Biochem Behav · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pbb.2013.01.019

Bibliografisk träff 2013-01-17

A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.

Mahableshwarkar AR, Jacobsen PL, Chen Y.

Curr Med Res Opin · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1185/03007995.2012.761600

Bibliografisk träff 2012-10-22

The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.

Bétry C, Pehrson AL, Etiévant A, Ebert B, Sánchez C, Haddjeri N.

Int J Neuropsychopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1017/s1461145712001058

Bibliografisk träff 2012-09-17

Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder.

Baldwin DS, Hansen T, Florea I.

Curr Med Res Opin · clinical trial; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1185/03007995.2012.725035

Bibliografisk träff 2012-09-11

A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.

Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y, Thase ME.

Int J Neuropsychopharmacol · meta-analysis; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1017/s1461145712000727

Bibliografisk träff 2012-08-15

Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States.

Rothschild AJ, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.

Eur Neuropsychopharmacol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.euroneuro.2012.07.011

Bibliografisk träff 2012-08-14

Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.

Bidzan L, Mahableshwarkar AR, Jacobsen P, Yan M, Sheehan DV.

Eur Neuropsychopharmacol · clinical trial, phase iii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/j.euroneuro.2012.07.012

Bibliografisk träff 2012-07-01

Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder.

Baldwin DS, Loft H, Florea I.

Int Clin Psychopharmacol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/yic.0b013e3283530ad7

Bibliografisk träff 2012-07-01

A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder.

Katona C, Hansen T, Olsen CK.

Int Clin Psychopharmacol · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1097/yic.0b013e3283542457

Bibliografisk träff 2012-07-01

A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.

Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.

J Clin Psychiatry · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.4088/jcp.11m07470

Bibliografisk träff 2012-05-20

Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study.

Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B, Sanchez C.

Eur Neuropsychopharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.euroneuro.2012.04.006

Bibliografisk träff 2012-04-24

The clinical pharmacokinetics of Lu AA21004 and its major metabolite in healthy young volunteers.

Areberg J, Søgaard B, Højer AM.

Basic Clin Pharmacol Toxicol · randomized controlled trial; journal article · DOI 10.1111/j.1742-7843.2012.00886.x

Bibliografisk träff 2012-04-11

Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004.

Hvenegaard MG, Bang-Andersen B, Pedersen H, Jørgensen M, Püschl A, Dalgaard L.

Drug Metab Dispos · journal article · DOI 10.1124/dmd.112.044610

Bibliografisk träff 2012-04-09

A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.

Boulenger JP, Loft H, Florea I.

J Psychopharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1177/0269881112441866

Bibliografisk träff 2011-12-30

A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).

Baldwin DS, Loft H, Dragheim M.

Eur Neuropsychopharmacol · research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1016/j.euroneuro.2011.11.008

Bibliografisk träff 2011-12-09

Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder.

Mørk A, Pehrson A, Brennum LT, Nielsen SM, Zhong H, Lassen AB, Miller S, Westrich L, Boyle NJ, Sánchez C, Fischer CW, Liebenberg N, Wegener G, Bundgaard C, Hogg S, Bang-Andersen B, Stensbøl TB.

J Pharmacol Exp Ther · journal article · DOI 10.1124/jpet.111.189068

Bibliografisk träff 2011-07-18

A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder.

Alvarez E, Perez V, Dragheim M, Loft H, Artigas F.

Int J Neuropsychopharmacol · comparative study; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1017/s1461145711001027